Document
IPR2018-01714, No. 1034-34 Exhibit - Browman et al, Modified adriamycin vincristine dexamethasone m VAD in primary refractory and relapsed plasma cell myeloma an NCI Canada pilot study, ...
Cite Document
IPR2018-01714, No. 1034-34 Exhibit - Browman et al, Modified adriamycin vincristine dexamethasone m VAD in primary refractory and relapsed plasma cell myeloma an NCI Canada pilot study, Br J Haematol,
+ More Snippets
Document
IPR2018-01714, No. 1006-6 Exhibit - Singhal et al, Antitumor Activity of Thalidomide in Refractory Multiple Myeloma, N Engl J Med, 3411565 1571 1999 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1006-6 Exhibit - Singhal et al, Antitumor Activity of Thalidomide in Refractory Multiple Myeloma, N Engl J Med, 3411565 1571 1999 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1029-29 Exhibit - Parameswaran et al, CCNU lomustine, idarubicin and dexamethasone CIDEX an effective oral regimen for the treatment of refractory or relapsed myeloma...
Cite Document
IPR2018-01714, No. 1029-29 Exhibit - Parameswaran et al, CCNU lomustine, idarubicin and dexamethasone CIDEX an effective oral regimen for the treatment of refractory or relapsed myeloma, Br J Haematol
+ More Snippets
Document
IPR2018-01714, No. 1014-14 Exhibit - Celgene Corp, Celgene Corporation Receives Orphan Drug Designation for RevimidTM For Multiple Myeloma, October 8, 2001 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1014-14 Exhibit - Celgene Corp, Celgene Corporation Receives Orphan Drug Designation for RevimidTM For Multiple Myeloma, October 8, 2001 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1003-3 Exhibit - Expert Declaration of Dr Guido Tricot (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1003-3 Exhibit - Expert Declaration of Dr Guido Tricot (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1043-43 Exhibit - Palumbo, A, et al, Lenalidomide A new therapy for multiple myeloma, Cancer Treatment Reviews 34283 291 2008 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1043-43 Exhibit - Palumbo, A, et al, Lenalidomide A new therapy for multiple myeloma, Cancer Treatment Reviews 34283 291 2008 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1049-49 Exhibit - Bell et al, Chapter 5 The Hematopoietic System and Development of Blood Cells, The Johns Hopkins Atlas of Human Functional Anatomy, 4th ed 1997 (P.T...
Cite Document
IPR2018-01714, No. 1049-49 Exhibit - Bell et al, Chapter 5 The Hematopoietic System and Development of Blood Cells, The Johns Hopkins Atlas of Human Functional Anatomy, 4th ed 1997 (P.T.A.B. Sep. 12,
+ More Snippets
Document
IPR2018-01714, No. 1039-39 Exhibit - Gay, F, et al, Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma a comparative analysis of 4...
Cite Document
IPR2018-01714, No. 1039-39 Exhibit - Gay, F, et al, Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma a comparative analysis of 411 patients, Bl
+ More Snippets
Document
IPR2018-01714, No. 1037-37 Exhibit - Dimopoulos, M, et al, Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma, N Engl J Med 357212123 2132 2007 (P.T.A.B. Sep. 1...
Cite Document
IPR2018-01714, No. 1037-37 Exhibit - Dimopoulos, M, et al, Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma, N Engl J Med 357212123 2132 2007 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1044-44 Exhibit - Dimopoulos, MA, et al, Long term follow up on overall survival from the MM 009 and MM 010 phase III trials of lenalidomide plus dexamethasone in patients...
Cite Document
IPR2018-01714, No. 1044-44 Exhibit - Dimopoulos, MA, et al, Long term follow up on overall survival from the MM 009 and MM 010 phase III trials of lenalidomide plus dexamethasone in patients with rela
+ More Snippets
Document
IPR2018-01714, No. 1052-52 Exhibit - US Provisional Application No 60380,842 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1052-52 Exhibit - US Provisional Application No 60380,842 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1053-53 Exhibit - Barlogie et al, Extended survival in advanced and refractory multiple myeloma after single agent thalidomide identification of prognostic factors in a phase ...
Cite Document
IPR2018-01714, No. 1053-53 Exhibit - Barlogie et al, Extended survival in advanced and refractory multiple myeloma after single agent thalidomide identification of prognostic factors in a phase 2 stud
+ More Snippets
Document
IPR2018-01714, No. 1002-2 Exhibit - Prosecution History excerpts for US Patent No 7,968,569 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1002-2 Exhibit - Prosecution History excerpts for US Patent No 7,968,569 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1059-63 Exhibit - Malpas and Rohatiner, Principles of Cancer Chemotherapy, Advances in Oncology 1317 350 1996 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1059-63 Exhibit - Malpas and Rohatiner, Principles of Cancer Chemotherapy, Advances in Oncology 1317 350 1996 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1022-22 Exhibit - Celesti et al, The association of cyclophosphamide and dexamethasone in advanced refractory multiple myeloma patients, Haematologica, 823351 353 19...
Cite Document
IPR2018-01714, No. 1022-22 Exhibit - Celesti et al, The association of cyclophosphamide and dexamethasone in advanced refractory multiple myeloma patients, Haematologica, 823351 353 1997 (P.T.A.B. Sep
+ More Snippets